share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax製藥 | 8-K:重大事件
美股SEC公告 ·  07/03 17:06

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc. received a notification from Nasdaq on June 28, 2024, indicating that the company's common stock had not met the minimum closing bid price of $1.00 per share over the past 30 consecutive business days, from May 15, 2024, to June 27, 2024. This failure to comply with Nasdaq Listing Rule 5550(a)(2) does not immediately affect the trading of Virpax's common stock, which continues to be listed under the ticker VRPX. The company has been granted a 180-day period, until December 26, 2024, to regain compliance. To achieve this, the closing bid price must be at or above $1.00 for at least ten consecutive business days during this period. Virpax Pharmaceuticals is considering measures, including a potential reverse stock split, to address the compliance issue and maintain its listing on The Nasdaq Capital Market.
Virpax Pharmaceuticals, Inc. received a notification from Nasdaq on June 28, 2024, indicating that the company's common stock had not met the minimum closing bid price of $1.00 per share over the past 30 consecutive business days, from May 15, 2024, to June 27, 2024. This failure to comply with Nasdaq Listing Rule 5550(a)(2) does not immediately affect the trading of Virpax's common stock, which continues to be listed under the ticker VRPX. The company has been granted a 180-day period, until December 26, 2024, to regain compliance. To achieve this, the closing bid price must be at or above $1.00 for at least ten consecutive business days during this period. Virpax Pharmaceuticals is considering measures, including a potential reverse stock split, to address the compliance issue and maintain its listing on The Nasdaq Capital Market.
2024年6月28日,Virpax藥品公司收到了納斯達克的通知,稱該公司的普通股30個連續營業日內未滿足1.00美元每股的最低收盤買盤價,這一未能遵守納斯達克清單規則5550(a)(2)並不立即影響Virpax普通股的交易,其仍在逐筆明細VRPX下繼續上市。該公司被授予180天的期限,直到2024年12月26日爲止,以恢復合規性。在此期間,收盤買盤價必須至少連續十個營業日爲1.00美元或以上。Virpax藥品公司正在考慮採取措施,包括潛在的股票拆分,以應對合規問題並在納斯達克資本市場維持其上市地位。
2024年6月28日,Virpax藥品公司收到了納斯達克的通知,稱該公司的普通股30個連續營業日內未滿足1.00美元每股的最低收盤買盤價,這一未能遵守納斯達克清單規則5550(a)(2)並不立即影響Virpax普通股的交易,其仍在逐筆明細VRPX下繼續上市。該公司被授予180天的期限,直到2024年12月26日爲止,以恢復合規性。在此期間,收盤買盤價必須至少連續十個營業日爲1.00美元或以上。Virpax藥品公司正在考慮採取措施,包括潛在的股票拆分,以應對合規問題並在納斯達克資本市場維持其上市地位。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息